ERBB2 and breast cancer: These are excellent biomarkers because of the contrast in their expression within invasive breast cancer compared with healthy tissue—ER is upregulated in ~75% of IBCs, with PR upregulated in ~70% and HER2 upregulated in 10–40% [25].